Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen finite-Lived Intangible Assets — Total Net Carrying Value ($M) ($M)
Form 10-Q / 10-K Goodwill and Other Intangible Assets Note (XBRL)
Latest, Q2 2026
19,777
Period ended Jun 30, 2026
Change on a year earlier
-17.3%
23,904 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
37
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Finite-Lived Intangible Assets — Total Net Carrying Value ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 19,777 | -17.3% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 20,669 | -16.2% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 21,566 | -19.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 22,429 | -19.4% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 23,904 | -17.6% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 24,664 | -18.4% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 26,639 | -15.2% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 27,830 | +114.2% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 29,022 | +112.0% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 30,222 | +110.1% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 31,423 | +108.5% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2023 | Sep 30, 2023 | 12,992 | +6.0% | Form 10-Q (filed 2023-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 13,692 | +6.1% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 14,384 | +6.2% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2022 | Dec 31, 2022 | 15,071 | +6.8% | Form 10-K (filed 2024-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 12,257 | -16.2% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 12,907 | -15.5% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 13,546 | -14.9% | Form 10-Q (filed 2022-04-28) ↗ |
| Q4 2021 | Dec 31, 2021 | 14,112 | -14.8% | Form 10-K (filed 2023-02-09) ↗ |
| Q3 2021 | Sep 30, 2021 | 14,629 | -15.1% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 15,278 | -14.7% | Form 10-Q (filed 2021-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 15,917 | -14.5% | Form 10-Q (filed 2021-04-28) ↗ |
| Q4 2020 | Dec 31, 2020 | 16,557 | -14.5% | Form 10-K (filed 2022-02-16) ↗ |
| Q3 2020 | Sep 30, 2020 | 17,224 | +159.9% | Form 10-Q (filed 2020-10-29) ↗ |
| Q2 2020 | Jun 30, 2020 | 17,918 | +165.1% | Form 10-Q (filed 2020-07-29) ↗ |
| Q1 2020 | Mar 31, 2020 | 18,623 | +163.4% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 19,359 | +162.0% | Form 10-Q (filed 2020-05-01) ↗ |
| Q3 2019 | Sep 30, 2019 | 6,626 | -14.2% | Form 10-Q (filed 2019-10-30) ↗ |
| Q2 2019 | Jun 30, 2019 | 6,758 | -16.1% | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 7,069 | -15.8% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 7,388 | -10.2% | Form 10-Q (filed 2019-10-30) ↗ |
| Q3 2018 | Sep 30, 2018 | 7,726 | -9.3% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jun 30, 2018 | 8,057 | -8.5% | Form 10-Q (filed 2018-07-27) ↗ |
| Q1 2018 | Mar 31, 2018 | 8,392 | -8.4% | Form 10-Q (filed 2018-04-25) ↗ |
| Q4 2017 | Dec 31, 2017 | 8,223 | -13.6% | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | 8,517 | -12.1% | 10-Q FY2017 (XBRL) ↗ |
| Q2 2017 | Jun 30, 2017 | 8,801 | -12.5% | 10-Q FY2017 (XBRL) ↗ |
| Q1 2017 | Mar 31, 2017 | 9,163 | -12.2% | 10-Q FY2017 (XBRL) ↗ |
| Q4 2016 | Dec 31, 2016 | 9,520 | -10.4% | Form 10-K (filed 2018-02-13) ↗ |
| Q3 2016 | Sep 30, 2016 | 9,690 | +2.3% | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 10,053 | +2.1% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 10,432 | +3.0% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | 10,626 | – | Form 10-K (filed 2017-02-14) ↗ |
| Q3 2015 | Sep 30, 2015 | 9,472 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 9,847 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 10,125 | – | 10-Q FY2015 (XBRL) ↗ |
Breakdown
What makes up finite-lived intangible assets — total net carrying value ($m)
- Finite-Lived Intangible Assets — Total Gross Carrying Value ($M)54,306 · Q2 2026
- Finite-Lived Intangible Assets — Total Accumulated Amortization ($M)34,529 · Q2 2026
- Developed Product Technology Rights — Net Carrying Value ($M)19,343 · Q2 2026
- Licensing Agreements — Net Carrying Value ($M)329 · Q2 2026
- Acquired R&D Technology Rights — Net Carrying Value ($M)105 · Q2 2026
- Marketing-Related Intangible Assets — Net Carrying Value ($M)0 · Q2 2026
Cite this data
StockData. (2026). Amgen Finite-Lived Intangible Assets — Total Net Carrying Value ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fl_intang_net_tot
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.